Skip to content

Depression research published in 2025

Page 27 of 39: studies 521 to 540 of 761, newest first. Back to the depression overview

Studies

[Interventional psychiatric procedures and novel substances for the treatment of affective disorders: An overview and outlook].

Therapeutische Umschau April 1, 2025 Tobias Bracht, Daniela Hubl, Kristina Adorjan et al. 1 citation

Depression is one of the most common mental disorders. The effectiveness of pharmacological and psychotherapeutic treatments is well documented. Remission rates are around 67 % for pharmacological antidepressant initial and secondary treatment of a depressive episode in unipolar disorders. However, patients with a depressive episode who do not respond to at least two successive attempts at...

DOI: 10.23785/TU.2025.02.005 (opens in new tab) Full text (opens in new tab) Treatment-resistant depression Electroconvulsive therapy ect Ketamine/esketamine Depression therapy innovations +3

Neuropharmacology of Ketamine and Its Use in the Treatment of Major Depressive Disorder: A Review.

Cureus April 1, 2025 Zach Papadopoulos 1 citation

Depression is a common yet potentially debilitating mood disorder with complex neurobiological underpinnings, including deficiencies in monoaminergic and glutamatergic signaling, overactivity of the lateral habenula, and dysregulation of brain-derived neurotrophic factor (BDNF) signaling. Ketamine has emerged as a mechanistically novel, effective, and rapidly acting antidepressant. Ketamine's...

Comparative Efficacy and Functional Outcomes of Psychedelic-Assisted Therapies in Treatment-Resistant Depression: A Systematic Review of Recent Clinical Trials.

Cureus April 1, 2025 Ciara Mimms, Kassandra Sotelo, Abdul Saboor Khaliq 1 citation

This systematic review explores the comparative efficacy and functional outcomes of psychedelic-assisted therapies in the management of treatment-resistant depression (TRD). Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive literature search was conducted across PubMed, Scopus, and Web of Science for randomized controlled...

A Systematic Literature Review of the Effectiveness of Mindfulness-Based Cognitive Therapy on Depression Among Older People

Jurnal Kesehatan March 31, 2025 Helena Patricia, Sharifah Munirah Syed Elias, Noor Azizah Binti Mohd Ali et al.

The worldwide population of older people is rising rapidly, with projections suggesting that by 2050, persons aged 60 and over will represent 22% of the entire population. Age-related outcomes are significantly exacerbated by frailty, susceptibility, and an elevated risk of depression. Mindfulness-Based Cognitive Therapy (MBCT) has become a feasible therapeutic approach, integrating cognitive...

Existing evidence for the use of psychedelics in patients with cancer and other serious illness: A narrative review.

Journal of Psychosocial Oncology March 26, 2025 Jennifer Bires

Mood disorders and existential distress impact those with cancer or a serious illness at higher rates than the general population. There have been limited pharmacological advances in recent years, and available psychological interventions vary in degree of impact and durability as a treatment modality in this population. A recent renaissance in psychedelic research has suggested that this class...

Innovative approaches in the treatment-resistant depression: exploring different therapeutic pathways.

GeroScience March 25, 2025 Anna Łysik, Katarzyna Logoń, Aleksandra Szczygieł et al. 8 citations

Treatment-resistant depression (TRD) remains a vital challenge in psychiatry, affecting a significant number of patients with major depressive disorder. Current pharmacological approaches often do not provide sufficient therapeutic results, prompting the need for innovative treatments. This review summarizes recent advances in TRD management, including non-pharmacological therapies such as...

Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l’étude

The Canadian Journal of Psychiatry March 25, 2025 Noah Chisamore, Erica Kaczmarek, Zoe Doyle et al. 1 citation

Objective: To compare changes in depression, anxiety, and suicidality symptoms after a single 25 mg oral dose of psilocybin between treatment-resistant depression participants not on antidepressants at screening to participants that discontinued antidepressant medications leading up to receiving psilocybin-assisted psychotherapy (PAP). Methods: Participants (n = 27) received at least one 25 mg...

DOI: 10.1177/07067437251328316 (opens in new tab) Treatment-resistant depression Depressive disorders Mood disorders Psilocybin-assisted psychotherapy +4

Monoamine neurotransmitter-related gene-based genome-wide association study of low-dose ketamine in patients with treatment-resistant depression.

Journal of Psychopharmacology March 24, 2025 Chung-Feng Kao, Shih-Jen Tsai, Tung-Ping Su et al. 1 citation

Low-dose ketamine is an N-methyl-D-aspartate receptor antagonist that exerts an antidepressant effect on patients with treatment-resistant depression (TRD). This antidepressant effect may extend beyond the glutamatergic hypothesis. Nevertheless, the roles of genes encoding other monoamine neurotransmitters (i.e., serotonin and dopamine) in the neuromechanism of low-dose ketamine remain unknown....

DOI: 10.1177/02698811251326939 (opens in new tab) Full text (opens in new tab) Treatment-resistant depression Neurotransmitter studies Psychiatric genomics Antidepressant mechanisms +4

A Critical Advantage of Hypnobirthing to Ameliorate Antenatal Depression: A Systematic Review and Meta-Analysis.

Healthcare March 23, 2025 Feni Betriana, Sunarno Sunarno, Wiwit Nurwidyaningtyas et al.

Pregnant women are likely to experience depression due to various factors. Hypnobirthing is a non-invasive therapy that can be used to treat depression during pregnancy. This study aims to systematically review the effect of hypnobirthing on antenatal depression. This study employs a systematic review following PRISMA guidelines. Articles were retrieved from PubMed, ScienceDirect, the Cochrane...

Oral Ketamine for the Treatment of Depression: A randomized controlled trial and meta-analysis

medRxiv Preprint Server March 21, 2025 Leo R. Silberbauer, Benjamin Eggerstorfer, Paul Michenthaler et al. 1 citation preprint

Background Ketamine represents a significant advancement in antidepressant therapy, but the commonly used intravenous and intranasal application routes currently limit its availability beyond specialized centers. By contrast, oral ketamine treatment might constitute an alternative that is easy to administer with established safety and efficacy for patients with chronic and severe pain at home.

DOI: 10.1101/2025.03.21.25324252 (opens in new tab) Full text (opens in new tab) Depression treatment Mental health management Mood disorder therapy Antidepressant care +18

Pharmacological Monotherapy for Depressive Disorders: Current and Future-A Narrative Review.

Medicina (Kaunas, Lithuania) March 21, 2025 Keming Gao, Evrim Bayrak Oruc, Buket Koparal 9 citations

Objective: To narratively review currently available antidepressants and future potential antidepressants as monotherapy for the treatment of depressive disorders. Methods: Selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), dopamine reuptake inhibitor (bupropion), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs) were...

DOI: 10.3390/medicina61040558 (opens in new tab) Full text (opens in new tab) N-methyl-d-aspartate receptor antagonists Anti-inflammatory agents Biomarker antidepressant therapy Depressive disorders +9

A Pre-Experimental Study to Assess the Impact of Mindfulness Meditation on Stress, Anxiety and Depression among the Senior Secondary Students Studying In Government School, Chandigarh

i-manager's Journal on Nursing March 20, 2025 Manpreet Kaur, Parul Sharma, Prince Harkaul et al.

A Pre-experimental study was conducted to assess the impact of Mindfulness Meditation on Stress, Anxiety and Depression among the Senior secondary Students Studying in Government School, Chandigarh. The objectives of the study are to identify the factors affecting stress, anxiety and depression among senior secondary students and to assess the impact of mindfulness meditation by comparing...

Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning‐Based Advanced Perspectives

Advanced Science March 20, 2025 Sung‐hyun Kim, Sumin Yang, Jeehye Jung et al. 5 citations

Abstract Mental disorders are a representative type of brain disorder, including anxiety, major depressive depression (MDD), and autism spectrum disorder (ASD), that are caused by multiple etiologies, including genetic heterogeneity, epigenetic dysregulation, and aberrant morphological and biochemical conditions. Psychedelic drugs such as psilocybin and lysergic acid diethylamide (LSD) have...

Can dextromethorphan-bupropion reduce mental pain in depressed individuals? A generating hypothesis overview perspective.

Annals of General Psychiatry March 17, 2025 Maurizio Pompili, Isabella Berardelli, Denise Erbuto et al.

Globally, major depressive disorder, or MDD, is a leading cause of disability. It negatively impacts social interactions and significantly limits daily functioning, ultimately reducing life satisfaction. The prevalence rate is about twice as high in women as in males. It is believed that the genesis of major depressive disorder is complicated and includes biological, genetic, environmental, and...

Holistic Healing Through Mindfulness: An Experimental Study Addressing Psychological Challenges Among Nurses Caring for Patients With COVID-19.

Journal of Holistic Nursing March 17, 2025 Hossam Alhawatmeh, Luay Abusaif, Maryam Alharrasi et al. 2 citations

Purpose: This study aimed to evaluate the effect of mHealth-based mindfulness intervention on trait mindfulness, stress, anxiety, and depression among Registered Nurses caring for patients with COVID-19 in Jordan. Method: Using a pretest-posttest parallel controlled design, 102 nurses from the King Abdullah University Hospital were randomly assigned into experimental (n = 51) and control (n =...

A Modern Overview of the Potential Therapeutic Effects of Psilocybin in the Treatment of Depressive Disorders, Treatment-Resistant Depression, and End-of-Life Distress

Cureus March 17, 2025 Fejzic Dino 1 citation

The purpose of this review is to provide a comprehensive overview of the current findings and data on the therapeutic effects of psilocybin, a naturally occurring psychedelic alkaloid primarily found in Psilocybe mushrooms. This review covers psilocybin's efficacy and safety profile, therapeutic effects, proposed indications and contraindications, drug-drug interactions, adverse reactions,...

Associations between hypothalamic-pituitary-adrenal (HPA) axis hormone levels, major depression features and antidepressant effects of ketamine.

Journal of Affective Disorders March 15, 2025 Polymnia Georgiou, Cristan A Farmer, Gustavo C Medeiros et al. 24 citations

Subanesthetic doses of (R,S)-ketamine (ketamine) have demonstrated rapid and robust antidepressant effects in individuals with depression. However, individual variability in response to ketamine exists, and current biomarkers of ketamine treatment response are not entirely understood. Preclinical evidence suggests a link between hypothalamic-pituitary-adrenal (HPA) axis activation, a...

DOI: 10.1016/j.jad.2024.12.036 (opens in new tab) Full text (opens in new tab) Depression Adrenocorticotropic hormone Corticotropin releasing factor Cortisol +4

Trends and characteristics in ketamine use among US adults with and without depression, 2015-2022.

Journal of Affective Disorders March 15, 2025 Kevin H. Yang, Wayne Kepner, Charles M Cleland et al. 19 citations

Ketamine's potential for treating depression has drawn increased clinical interest in recent years. However, despite growing therapeutic use, recreational use among individuals with depression remain underexplored. We analyzed data from the 2015-2022 National Survey on Drug Use and Health focusing on adults in the US. Trends in past-year ketamine use, overall and by depression status, were...

DOI: 10.1016/j.jad.2024.12.108 (opens in new tab) Full text (opens in new tab) Depression Nationally representative samples Ketamine-use-trends Mental-health-epidemiology +2

Mice lacking the serotonin transporter do not respond to the behavioural effects of psilocybin.

European Journal of Pharmacology March 15, 2025 James J Gattuso, Carey Wilson, Shanshan Li et al. 16 citations

Psilocybin is a serotonergic psychedelic with therapeutic potential for several neuropsychiatric disorders, including depression and anxiety disorders. Serotonin transporter (5-HTT) knockout mice (KO) are a well-validated mouse model of anxiety/depression and are relevant to both chronic treatment with serotonin transporter reuptake inhibitors (SSRIs) and polymorphisms in the serotonin...

Person-centred care during treatment with nasal esketamine - a qualitative study.

BMC Nursing March 14, 2025 Lina Klysing, Ingrid Larsson, Katrin Häggström Westberg 2 citations

Patients suffering from treatment-resistant depression may be treated with nasal esketamine. The treatment requires administration in a healthcare facility and monitoring by a nurse. Existing research has mainly focused on the clinical effect of nasal esketamine, while less is known about patients' experiences of treatment. A person-centred framework provides valuable insights into care and...

DOI: 10.1186/s12912-025-02943-y (opens in new tab) Full text (opens in new tab) Intranasal ketamine Nursing Nasal esketamine Person-centred care +4